Análisis farmacoeconómico del tratamiento de la osteoporosis postmenopáusica con risedronato o alendronato
- W.M. Hart
- Carlos Rubio Terrés
- A. Burrell
- I. Arístegui Ruiz
- Fernando Escobar Jiménez
ISSN: 1132-8460
Année de publication: 2002
Volumen: 11
Número: 3
Pages: 97-104
Type: Article
D'autres publications dans: Revista Española de Enfermedades Metabólicas Oseas
Résumé
A cost-effectiveness analysis of the treatment of post-menopausal osteoporosis with risedronate and once-a-week alendronate was performed, using a Markov model and Spanish costs. The risk of hip fracture, in patients with or without previous vertebral fracture, was reduced by 60% and 40% with risedronate and 51% and 21% with alendronate, respectivelly. The reduction in the risk of vertebral fracture in patients with previous vertebral fracture was 45% and 55%, with risedronate and alendronate. The cost per hip fracture avoided (after onset of treatment in women aged 70 years, with or without vertebral fracture, and after 10 years of treatment) was 54,134 and 84,287 euros, respectively with risedronate. With alendronate the cost per hip fracture avoided was greater: 67,853 and 173,748 euros, respectively. The cost per quality adjusted life-year (QALY) was also lower with risedronate (43,601-61,064 euros) than with alendronate (49,483-88,634 euros) in patients with or without previous vertebral fracture, respectively. Risedronate is more cost-effective than once-a-week alendronate.